Skip to content

Home Search Authors Pakistan News Saved

SciRah

SciRah does not host or store research papers. Results come live from free, official scholarly APIs, and every paper links back to its original source.

Data sources

OpenAlex
Semantic Scholar
Crossref
CORE
arXiv
PubMed

Privacy policy Terms of service

F. Montemurro · SciRah

Researcher profile · Semantic Scholar

F. Montemurro

Share profile

F. Montemurro — researcher profile on SciRah

h-index: 48
Works: 324
Citations: 8,187

Most-cited papers

Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced/metastatic triple-negative breast cancer.
D. Miles, J. Gligorov, F. André, D. Cameron +155 more
2021Annals of Oncology597 citations Open access
Semantic Scholar
Trastuzumab emtansine (T-DM1) in patients with HER2-positive metastatic breast cancer and brain metastases: exploratory final analysis of cohort 1 from KAMILLA, a single-arm phase IIIb clinical trial.
F. Montemurro, S. Delaloge, C. Barrios, R. Wuerstlein +8 more
2020Annals of Oncology336 citations Open access
Semantic Scholar
Genomics to select treatment for patients with metastatic breast cancer
F. André, T. Filleron, M. Kamal, F. Mosele +35 more
2022Nature150 citations
Semantic Scholar
Preliminary safety and efficacy of first-line pertuzumab combined with trastuzumab and taxane therapy for HER2-positive locally recurrent or metastatic breast cancer (PERUSE).
T. Bachelot, E. Ciruelos, A. Schneeweiss, F. Puglisi +288 more
2019Annals of Oncology108 citations Open access
Semantic Scholar
Neoadjuvant or adjuvant chemotherapy in early breast cancer?
F. Montemurro, Imperia Nuzzolese, R. Ponzone
2020Expert Opinion on Pharmacotherapy105 citations
Semantic Scholar
Toxicity profile of antibody-drug conjugates in breast cancer: practical considerations
Andrea D'Arienzo, Annarita Verrazzo, M. Pagliuca, F. Napolitano +9 more
2023EClinicalMedicine103 citations Open access
Semantic Scholar
Safety of trastuzumab emtansine (T-DM1) in patients with HER2-positive advanced breast cancer: Primary results from the KAMILLA study cohort 1.
F. Montemurro, P. Ellis, A. Antón, R. Wuerstlein +8 more
2019European Journal of Cancer97 citations Open access
Semantic Scholar
Surgical and Oncologic Outcomes of Robotic and Conventional Nipple-Sparing Mastectomy with Immediate Reconstruction: International Multicenter Pooled Data Analysis
Hyung Seok Park, Jeea Lee, H. Lai, J. Park +10 more
2022Annals of Surgical Oncology71 citations Open access
Semantic Scholar
Extended therapy with letrozole as adjuvant treatment of postmenopausal patients with early-stage breast cancer: a multicentre, open-label, randomised, phase 3 trial.
L. Del Mastro, M. Mansutti, G. Bisagni, R. Ponzone +24 more
2021The Lancet Oncology71 citations
Semantic Scholar
Should All Patients With HR-Positive HER2-Negative Metastatic Breast Cancer Receive CDK 4/6 Inhibitor As First-Line Based Therapy? A Network Meta-Analysis of Data from the PALOMA 2, MONALEESA 2, MONALEESA 7, MONARCH 3, FALCON, SWOG and FACT Trials
V. Rossi, P. Berchialla, D. Giannarelli, C. Nisticò +10 more
2019Cancers70 citations Open access
Semantic Scholar
Final results of the double-blind placebo-controlled randomized phase 2 LOTUS trial of first-line ipatasertib plus paclitaxel for inoperable locally advanced/metastatic triple-negative breast cancer
R. Dent, M. Oliveira, S. Isakoff, S. Im +58 more
2021Breast Cancer Research and Treatment69 citations
Semantic Scholar
Estrogen deprivation effects of endocrine therapy in breast cancer patients: Incidence, management and outcome.
L. Cucciniello, G. Garufi, Rossana Di Rienzo, C. Martinelli +7 more
2023Cancer Treatment Reviews62 citations Open access
Semantic Scholar
“Metastatic Cancer of Unknown Primary” or “Primary Metastatic Cancer”?
Stefan Kolling, Ferdinando Ventre, E. Geuna, M. Milan +4 more
2020Frontiers in Oncology61 citations Open access
Semantic Scholar
Fluorouracil and dose-dense adjuvant chemotherapy in patients with early-stage breast cancer (GIM2): end-of-study results from a randomised, phase 3 trial.
L. Del Mastro, F. Poggio, E. Blondeaux, S. De Placido +24 more
2022The Lancet Oncology48 citations
Semantic Scholar
Integrative genomic and transcriptomic analyses illuminate the ontology of HER2-low breast carcinomas
E. Berrino, L. Annaratone, S. Bellomo, G. Ferrero +16 more
2022Genome Medicine42 citations Open access
Semantic Scholar
Immunotherapy for HER2-Positive Breast Cancer: Clinical Evidence and Future Perspectives
E. Agostinetto, F. Montemurro, F. Puglisi, C. Criscitiello +6 more
2022Cancers41 citations Open access
Semantic Scholar
Efficacy and Safety of Trastuzumab Emtansine Plus Capecitabine vs Trastuzumab Emtansine Alone in Patients With Previously Treated ERBB2 (HER2)-Positive Metastatic Breast Cancer
J. Cortés, V. Diéras, S. Lorenzen, F. Montemurro +16 more
2020JAMA Oncology36 citations Open access
Semantic Scholar
Dysgeusia in Patients with Breast Cancer Treated with Chemotherapy—A Narrative Review
M. Pellegrini, F. Merlo, E. Agnello, T. Monge +6 more
2023Nutrients33 citations Open access
Semantic Scholar
Serum thymidine kinase activity in patients with HR-positive/HER2-negative advanced breast cancer treated with ribociclib plus letrozole: Results from the prospective BioItaLEE trial.
L. Malorni, G. Bianchini, R. Caputo, A. Zambelli +17 more
2023European Journal of Cancer32 citations Open access
Semantic Scholar
Prognostic and clinical impact of the endocrine resistance/sensitivity classification according to international consensus guidelines for advanced breast cancer: an individual patient-level analysis from the Mammella InterGruppo (MIG) and Gruppo Italiano Mammella (GIM) studies
M. Lambertini, E. Blondeaux, G. Bisagni, S. Mura +25 more
2023EClinicalMedicine31 citations Open access
Semantic Scholar
Real-world histopathological approach to malignancy of undefined primary origin (MUO) to diagnose cancers of unknown primary (CUPs)
A. Pisacane, E. Cascardi, E. Berrino, Alessio Polidori +12 more
2022Virchows Archiv29 citations Open access
Semantic Scholar
Cancer of unknown primary stem-like cells model multi-organ metastasis and unveil liability to MEK inhibition
F. Verginelli, A. Pisacane, G. Gambardella, A. D'Ambrosio +13 more
2021Nature Communications24 citations Open access
Semantic Scholar
Inclusion of Platinum Agents in Neoadjuvant Chemotherapy Regimens for Triple-Negative Breast Cancer Patients: Development of GRADE (Grades of Recommendation, Assessment, Development and Evaluation) Recommendation by the Italian Association of Medical Oncology (AIOM)
M. Dieci, L. Del Mastro, M. Cinquini, F. Montemurro +13 more
2019Cancers24 citations Open access
Semantic Scholar
Epidemiology, clinical outcomes, and unmet needs of patients with human epidermal growth factor receptor 2-positive breast cancer and brain metastases: A systematic literature review.
V. Müller, R. Bartsch, N. Lin, F. Montemurro +2 more
2023Cancer Treatment Reviews22 citations Open access
Semantic Scholar
Final results of the global and Asia cohorts of KAMILLA, a phase IIIB safety trial of trastuzumab emtansine in patients with HER2-positive advanced breast cancer
R. Wuerstlein, P. Ellis, F. Montemurro, A. A. Torres +12 more
2022ESMO Open22 citations Open access
Semantic Scholar
Dose‐dense adjuvant chemotherapy in HER2‐positive early breast cancer patients before and after the introduction of trastuzumab: Exploratory analysis of the GIM2 trial
M. Lambertini, F. Poggio, M. Bruzzone, B. Conte +15 more
2019International Journal of Cancer21 citations Open access
Semantic Scholar
T-DM1 versus pertuzumab, trastuzumab and a taxane as first-line therapy of early-relapsed HER2-positive metastatic breast cancer: an Italian multicenter observational study
F. Schettini, B. Conte, G. Buono, P. De Placido +24 more
2021ESMO Open20 citations Open access
Semantic Scholar
Abstract GS3-07: Circulating tumor DNA (ctDNA) dynamics in patients with hormone receptor positive (HR+)/HER2 negative (HER2-) advanced breast cancer (aBC) treated in first line with ribociclib (R) and letrozole (L) in the BioItaLEE trial
G. Bianchini, L. Malorni, G. Arpino, A. Zambelli +16 more
2022Cancer Research19 citations
Semantic Scholar
Exploratory analysis of circulating cytokines in patients with metastatic breast cancer treated with eribulin: the TRANSERI-GONO (Gruppo Oncologico del Nord Ovest) study
O. Garrone, A. Michelotti, M. Paccagnella, F. Montemurro +10 more
2020ESMO Open19 citations Open access
Semantic Scholar
Phase II study of eribulin in combination with gemcitabine for the treatment of patients with locally advanced or metastatic triple negative breast cancer (ERIGE trial). Clinical and pharmacogenetic results on behalf of the Gruppo Oncologico Italiano di Ricerca Clinica (GOIRC)
B. Pellegrino, L. Cavanna, D. Boggiani, C. Zamagni +18 more
2020ESMO Open19 citations Open access
Semantic Scholar
Oncotype DX results increase concordance in adjuvant chemotherapy recommendations for early-stage breast cancer
L. Licata, G. Viale, M. Giuliano, G. Curigliano +18 more
2023npj Breast Cancer17 citations Open access
Semantic Scholar
Robot-assisted mastectomy: next major advance in breast cancer surgery.
A. Toesca, Hyung Seok Park, J. Ryu, Y. Kim +13 more
2023British Journal of Surgery16 citations Open access
Semantic Scholar
Attrition in metastatic breast cancer: a metric to be reported in randomised clinical trials?
Imperia Nuzzolese, F. Montemurro
2020The Lancet Oncology16 citations
Semantic Scholar
Reoperation rate after breast conserving surgery as quality indicator in breast cancer treatment: A reappraisal
F. Tamburelli, F. Maggiorotto, C. Marchiò, D. Balmativola +9 more
2020Breast15 citations Open access
Semantic Scholar
T-DM1 after Pertuzumab plus Trastuzumab: Treatment Sequence-Induced Selection Bias in HER2-Positive Metastatic Breast Cancer
T. Sanglier, A. Fabi, C. Flores, Evelyn M. Flahavan +3 more
2022Cancers14 citations Open access
Semantic Scholar
MiR-100 is a predictor of endocrine responsiveness and prognosis in patients with operable luminal breast cancer
Annalisa Petrelli, S. Bellomo, I. Sarotto, Franziska Kubatzki +16 more
2020ESMO Open14 citations Open access
Semantic Scholar
PARP-inhibitors for BRCA1/2-related advanced HER2-negative breast cancer: A meta-analysis and GRADE recommendations by the Italian Association of Medical Oncology
F. Miglietta, M. Cinquini, M. Dieci, L. Cortesi +14 more
2022Breast12 citations Open access
Semantic Scholar
Randomized, open-label, phase II, biomarker study of immune-mediated mechanism of action of neoadjuvant subcutaneous trastuzumab in patients with locally advanced, inflammatory, or early HER2-positive breast cancer—Immun-HER trial (GOIRC-01-2016)
Benedetta Pellegrino, C. Tommasi, O. Serra, Stefania Gori +20 more
2023Journal for ImmunoTherapy of Cancer11 citations Open access
Semantic Scholar
Composite risk and benefit from adjuvant dose-dense chemotherapy in hormone receptor-positive breast cancer
F. Puglisi, L. Gerratana, M. Lambertini, M. Ceppi +17 more
2021npj Breast Cancer11 citations Open access
Semantic Scholar
The Clinical Efficacy and Safety of Neratinib in Combination with Capecitabine for the Treatment of Adult Patients with Advanced or Metastatic HER2-Positive Breast Cancer
Giovanna Chilà, Vincenzo Guarini, D. Galizia, E. Geuna +1 more
2021Drug Design, Development and Therapy11 citations Open access
Semantic Scholar
Cancer of Unknown Primary (CUP): genetic evidence for a novel nosological entity? A case report
S. Benvenuti, M. Milan, E. Geuna, A. Pisacane +7 more
2020EMBO Molecular Medicine11 citations Open access
Semantic Scholar
Effect of dose-dense adjuvant chemotherapy in hormone receptor positive/HER2-negative early breast cancer patients according to immunohistochemically defined luminal subtype: an exploratory analysis of the GIM2 trial.
B. Conte, M. Bruzzone, M. Lambertini, F. Poggio +17 more
2020European Journal of Cancer11 citations
Semantic Scholar
Gender minorities in breast cancer – Clinical trials enrollment disparities: Focus on male, transgender and gender diverse patients
F. Miglietta, L. Pontolillo, C. de Angelis, R. Caputo +15 more
2024Breast9 citations Open access
Semantic Scholar
Clinical outcomes of patients with breast cancer relapsing after (neo)adjuvant trastuzumab and receiving trastuzumab rechallenge or lapatinib-based therapy: a multicentre retrospective cohort study
E. Blondeaux, A. Ferreira, F. Poggio, F. Puglisi +13 more
2020ESMO Open8 citations Open access
Semantic Scholar
What is the best pharmacotherapeutic strategy for HER-2 positive breast cancer?
G. Giannone, A. Milani, E. Geuna, D. Galizia +2 more
2018Expert Opinion on Pharmacotherapy8 citations Open access
Semantic Scholar
Trastuzumab emtansine vs lapatinib and capecitabine in HER2-positive metastatic breast cancer brain metastases: A real-world study
T. Sanglier, Jin-Suk Shim, N. Lamarre, C. Peña-Murillo +2 more
2023Breast7 citations Open access
Semantic Scholar
Extended Adjuvant Endocrine Treatment in Luminal Breast Cancers in the Era of Genomic Tests
Mariarosaria Saponaro, Luigi Annunziata, A. Turla, I. Viganò +9 more
2022International Journal of Molecular Sciences7 citations Open access
Semantic Scholar
Impact of Baseline and On-Treatment Glycemia on Everolimus-Exemestane Efficacy in Patients with Hormone Receptor–Positive Advanced Breast Cancer (EVERMET)
C. Vernieri, F. Nichetti, L. Lalli, L. Moscetti +43 more
2021Clinical Cancer Research7 citations Open access
Semantic Scholar
Endocrine therapy for hormone receptor-positive, HER2-negative metastatic breast cancer: extending endocrine sensitivity.
A. Frassoldati, L. Biganzoli, R. Bordonaro, S. Cinieri +12 more
2019Future Oncology7 citations Open access
Semantic Scholar
Long-term toxicity profile of trastuzumab emtansine (T-DM1): A multicenter real-life study.
G. Buono, A. Fabi, L. Del Mastro, K. Cannita +16 more
2019Journal of Clinical Oncology6 citations
Semantic Scholar

Frequent co-authors

Invite them to SciRah by sharing their profile.

L. Del Mastro×22
Invite
L. Del Mastro — researcher profile on SciRah
F. Puglisi×18
Invite
F. Puglisi — researcher profile on SciRah
M. de Laurentiis×12
Invite
M. de Laurentiis — researcher profile on SciRah
G. Arpino×10
Invite
G. Arpino — researcher profile on SciRah

×9

Invite

A. Fabi — researcher profile on SciRah

M. Lambertini×8

Invite

M. Lambertini — researcher profile on SciRah

Invite

E. Geuna — researcher profile on SciRah

Invite

A. Sapino — researcher profile on SciRah

Invite

A. Zambelli — researcher profile on SciRah

A. Frassoldati×7

Invite

A. Frassoldati — researcher profile on SciRah

Invite

M. Giuliano — researcher profile on SciRah

Invite

F. Cognetti — researcher profile on SciRah